Two-year EPIC Skin Study results presented at ACRO 2026
OncoBeta presented final 24-month outcomes from the Phase IV EPIC Skin Study at the American College of Radiation Oncology (ACRO) 2026 Annual Meeting during a scientific breakfast symposium. The data, presented by A/Prof Siddhartha Baxi, showed durable clinical response, tolerability, cosmetic outcomes and patient-reported experience following a single treatment session with Rhenium-SCT® for non-melanoma skin cancer.
View media release: EPIC_Skin_Study_Results_at_ACRO_2026
View presentation: ACRO_2026_presentation_OncoBeta.pdf